close
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

AbCellera Biologics Inc. - Common Shares (NQ:ABCL)

3.620 -0.120 (-3.21%)
Streaming Delayed Price Updated: 4:00 PM EST, Dec 12, 2025 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about AbCellera Biologics Inc. - Common Shares

< Previous 1 2 3 4 5 6 7 8 9 10 11 Next >
News headline image
AbCellera Presents Data Showing Preclinical Efficacy of PSMA x CD3 T-Cell Engagers at AACR 2025
From AbCellera Biologics Inc.
Via Business Wire
News headline image
AbCellera to Participate at Upcoming Investor Conferences in May and June
From AbCellera Biologics Inc.
Via Business Wire
News headline image
AbCellera to Report First Quarter 2025 Financial Results on May 8, 2025
From AbCellera Biologics Inc.
Via Business Wire
News headline image
Earnings Scheduled For February 27, 2025 ↗
 
Via Benzinga
News headline image
AbCellera Announces Presentation of In Vivo Data on PSMA x CD3 T-Cell Engagers at AACR 2025
From AbCellera Biologics Inc.
Via Business Wire
News headline image
AbCellera Biologics (ABCL) Q4 2024 Earnings Call Transcript ↗
ABCL earnings call for the period ending December 31, 2024. 
Via The Motley Fool
Topics Earnings
News headline image
AbCellera Reports Full Year 2024 Business Results
From AbCellera Biologics Inc.
Via Business Wire
News headline image
AbCellera to Participate at Upcoming Investor Conferences in March
From AbCellera Biologics Inc.
Via Business Wire
News headline image
AbCellera to Report Full Year 2024 Financial Results on February 27, 2025
From AbCellera Biologics Inc.
Via Business Wire
News headline image
AbCellera Expands Collaboration with AbbVie to Develop Novel T-Cell Engagers for Oncology
From AbCellera Biologics Inc.
Via Business Wire
News headline image
AbCellera to Present at Upcoming Investor Conferences in December and January
From AbCellera Biologics Inc.
Via Business Wire
News headline image
AbCellera Presents Data on Applications of T-Cell Engager Platform at SITC 2024
From AbCellera Biologics Inc.
Via Business Wire
News headline image
AbCellera Biologics (ABCL) Q3 2024 Earnings Call Transcript ↗
ABCL earnings call for the period ending September 30, 2024. 
Via The Motley Fool
Topics Earnings
News headline image
AbCellera Reports Q3 2024 Business Results
From AbCellera Biologics Inc.
Via Business Wire
News headline image
AbCellera to Present at Upcoming Investor Conferences in November 2024
From AbCellera Biologics Inc.
Via Business Wire
News headline image
AbCellera Announces Presentation on T-cell Engager Platform at the Society for Immunotherapy of Cancer (SITC) Annual Meeting 2024
From AbCellera Biologics Inc.
Via Business Wire
News headline image
AbCellera to Report Third Quarter 2024 Financial Results on November 4, 2024
From AbCellera Biologics Inc.
Via Business Wire
News headline image
AI-Focused Drug Discovery Stocks +6% Last Week Vs. -8% Previous Week ↗
The AI-powered drug discovery process is expected to grow by a CAGR of 30% between now and 2030 which should result in as many as 50 novel therapies being brought to market by then and generate annual... 
Via Talk Markets
News headline image
AI-Focused Drug Discovery Stocks Portfolio -8% W/e Sept 6th ↗
The AI-powered drug discovery process is expected to grow by a CAGR of 30% between now and 2030 and should result in as many as 50 novel therapies being brought to market by then and generate annual... 
Via Talk Markets
News headline image
Our AI-Focused Drug Discovery Stocks Portfolio Down 8% In August; Down 6.7% Yesterday Alone! ↗
The August ISM manufacturing index reported on Tuesday that figures came in below consensus expectation. That raised fears about the strength of the economy, driving down our Our AI-Focused Drug... 
Via Talk Markets
Topics Economy
News headline image
AbCellera to Present at Upcoming Investor Conferences in September
From AbCellera Biologics Inc.
Via Business Wire
News headline image
Our AI-Focused Drug Discovery Stocks Portfolio Was Up Almost 7% Last Week ↗
The AI-powered drug discovery process is expected to grow by a CAGR of 30% between now and 2030. 
Via Talk Markets
News headline image
This Globant Analyst Is No Longer Bullish; Here Are Top 5 Downgrades For Tuesday ↗
 
Via Benzinga
News headline image
AI-Focused Drug Discovery Stocks Portfolio Hit Hard: Down 14% MTD ↗
The AI-powered drug discovery process is expected to grow by a 30% CAGR between now and 2030 which should result in approximately 50 novel therapies and generate annual sales in excess of $50 billion... 
Via Talk Markets
News headline image
AbCellera Biologics (ABCL) Q2 2024 Earnings Call Transcript ↗
ABCL earnings call for the period ending June 30, 2024. 
Via The Motley Fool
Topics Earnings
News headline image
AbCellera Reports Q2 2024 Business Results
From AbCellera Biologics Inc.
Via Business Wire
News headline image
AbCellera and Lilly Expand Collaboration to Develop Antibody Medicines
From AbCellera Biologics Inc.
Via Business Wire
News headline image
AI-Focused Drug Discovery Stocks Portfolio Up 7% Last Week; Up 19% MTD ↗
The AI-powered drug discovery process is expected to grow by a CAGR of 30% by 2030. 
Via Talk Markets
News headline image
"Bubble" In AI/Semiconductor Stocks Began To Re-Inflate On Friday ↗
A week ago it was suggested that the AI/semiconductor stocks sector was oversold. The decline bottomed on Wednesday and by the close of business this past Friday the sector had rebounded nicely almost... 
Via Talk Markets
News headline image
Billionaires Are Buying These 2 Beaten-Down Stocks. Are They Smart Buys for Your Portfolio? ↗
The Baker brothers are billionaires with a successful track record in the biopharmaceutical industry. 
Via The Motley Fool
< Previous 1 2 3 4 5 6 7 8 9 10 11 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.

Starting at $3.75/week.

Subscribe Today